-
The incidence and predictive value of abnormal liver function tests (LFTs) in patients with acute decompensated heart failure is poorly understood. Thus, these investigators from the SURVIVE study report their experience in patients with acute decompensated heart failure due to systolic dysfunction treated with positive inotropic infusions
-
There is considerable debate concerning the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Clearly, there is benefit to DAPT early after PCI.
-
Newer biomarkers such as B-type natriuretic peptide (BNP) and high-sensitive troponins have been shown to be of prognostic value in patients with cardiovascular disease. These investigators from central Europe sought to determine if they were of value in risk stratification for non-cardiac surgery.
-
The prevalence and natural history of aortic stenosis (AS) are well known. However, there is a paucity of data about the natural history of combined AS and aortic regurgitation (AR). AS and AR confer differing types of stress on the left ventricle, and it stands to reason that the combination may result in worse outcomes than either AS or AR alone.
-
Chelation therapy for cardiovascular disease; statins and kidney injuries; chlorthalidone for hypertension; and FDA actions.
-
In this paper, the authors report the results of a study that examined the impact of yoga training on patients with paroxysmal atrial fibrillation (AF). The authors enrolled 101 patients with paroxysmal AF who were on a stable medical regimen.
-
-
Regardless of the caffeine status, coffee intake was associated with reduced risk of type 2 diabetes while sugar-sweetened beverages were associated with a higher risk.
-
A new topical agent is available for the treatment of actinic keratosis (AK). Ingenol mebutate is a macrocyclic diterpene ester found in the sap of Euphorbia peplus, a common plant found in Africa, Europe, and Asia.
-
Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
